drugset / Trial / NCT00125515

Memantine and Naltrexone Treatment for Opioid Dependence

NCT00125515

RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this study is to test the efficacy of memantine (a noncompetitive NMDA receptor antagonist) as an adjunct to the maintenance treatment with naltrexone in detoxified heroin-dependent individuals.

Timeline

Start
2005-06
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Memantine Unknown 15 mg
Comparator Memantine Unknown 30 mg
Comparator Naltrexone Small molecule 50 mg Oral

Indications